CROI 2012: Tenofovir Pro-drug GS-7340 Shows Good Efficacy, Safety, and Suitability for Coformulation
- Details
- Category: Experimental HIV Drugs
- Published on Thursday, 08 March 2012 00:00
- Written by Liz Highleyman
GS-7340, a pro-drug of tenofovir that reaches higher concentrations in cells, was shown to have superior efficacy and may be more suitable for inclusion in coformulated regimens, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.
CROI 2012: PEPFAR Funding Linked to Lower Death Rate from All Causes in Africa
- Details
- Category: HIV Policy & Advocacy
- Published on Thursday, 08 March 2012 00:00
- Written by Keith Alcorn
PEPFAR funding for HIV programs lowered the risk of death in countries receiving funds by around 16% between 2004 and 2008, without any clear indication that funding for HIV was having a negative effect on the ability to fight other diseases, Eran Bendavid of Stanford University reported on Wednesday at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.
CROI 2012: HIV Cure Research -- A New Era of Treatment [VIDEO]
- Details
- Category: Search for a Cure
- Published on Thursday, 08 March 2012 00:00
- Written by Gregory Fowler
Researchers presented several studies aimed at eradication or functional cure of HIV on Thursday at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) in Seattle.
CROI 2012: Studies Advance Development of Microbicides for HIV Prevention
- Details
- Category: HIV Prevention
- Published on Thursday, 08 March 2012 00:00
- Written by Paul Dalton
A pair of studies presented in an oral session at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) taking place this week in Seattle addressed the safety and acceptability of experimental microbicide preparations. Both studies found the microbicides to be well tolerated and acceptable.
CROI 2012: Final Partners PrEP Results Confirm Efficacy of Oral Antiretrovirals for HIV Prevention
- Details
- Category: HIV Prevention
- Published on Wednesday, 07 March 2012 00:00
- Written by Paul Dalton
Daily, oral pre-exposure prophylaxis (PrEP) using either tenofovir (Viread) or tenofovir/emtricitabine (Truvada) was highly effective at preventing HIV infection in a large study of serodiscordant heterosexual couples in sub-Saharan Africa, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.
More Articles...
- CROI 2012: Hormonal Contraception May Raise HIV Risk for Women, but Uncertainty Remains
- CROI 2012: GS-7977 Rapidly Suppresses HCV, but Most Patients Relapse after Stopping Treatment
- CROI 2012: Telaprevir and Boceprevir Improve Sustained Response Rates in HIV/HCV Coinfected Patients
- CROI 2012: New Hepatitis C Drugs in Clinical Practice [VIDEO]
Web Design and Development by